Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Discussion
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by narmacon Nov 13, 2023 9:05am
150 Views
Post# 35731603

RE:RE:RE:RE:Discussion

RE:RE:RE:RE:Discussion Nothing has developed from what research I have done. I have contacted dozens of shareholders and all understand that the situation BTI is in clearly lands in the lap of our CEO DR! As you, I am hoping deep pocket shareholders afford us minions a tad of input going forward as part of a colaborated effort to resurrect. 

No one on this board is or ever has been responsible for BTIs failure to launch!  If the science does not work we have to back track to find out what would make Mei Mei think it ever did!

After speaking with the CEOs over the past decade they noted no issue with the science. Their professional credentials tell me if all was a lie then they possibly stand to absorb huge risk later. 

The future is still unkown. And,, possibilities do exist!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities